323 related articles for article (PubMed ID: 36264554)
1. Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer: A Narrative Review.
Krebs MG; Malapelle U; André F; Paz-Ares L; Schuler M; Thomas DM; Vainer G; Yoshino T; Rolfo C
JAMA Oncol; 2022 Dec; 8(12):1830-1839. PubMed ID: 36264554
[TBL] [Abstract][Full Text] [Related]
2. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
3. Liquid biopsy: current technology and clinical applications.
Nikanjam M; Kato S; Kurzrock R
J Hematol Oncol; 2022 Sep; 15(1):131. PubMed ID: 36096847
[TBL] [Abstract][Full Text] [Related]
4. Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA.
Gale D; Lawson ARJ; Howarth K; Madi M; Durham B; Smalley S; Calaway J; Blais S; Jones G; Clark J; Dimitrov P; Pugh M; Woodhouse S; Epstein M; Fernandez-Gonzalez A; Whale AS; Huggett JF; Foy CA; Jones GM; Raveh-Amit H; Schmitt K; Devonshire A; Green E; Forshew T; Plagnol V; Rosenfeld N
PLoS One; 2018; 13(3):e0194630. PubMed ID: 29547634
[TBL] [Abstract][Full Text] [Related]
5. Liquid biopsy and its role in an advanced clinical trial for lung cancer.
Johann DJ; Steliga M; Shin IJ; Yoon D; Arnaoutakis K; Hutchins L; Liu M; Liem J; Walker K; Pereira A; Yang M; Jeffus SK; Peterson E; Xu J
Exp Biol Med (Maywood); 2018 Feb; 243(3):262-271. PubMed ID: 29405770
[TBL] [Abstract][Full Text] [Related]
6. Liquid Biopsy and Lung Cancer.
Pisapia P; Malapelle U; Troncone G
Acta Cytol; 2019; 63(6):489-496. PubMed ID: 30566947
[TBL] [Abstract][Full Text] [Related]
7. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
Shields MD; Chen K; Dutcher G; Patel I; Pellini B
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
[TBL] [Abstract][Full Text] [Related]
8. Liquid biopsy in lymphoma: Molecular methods and clinical applications.
Cirillo M; Craig AFM; Borchmann S; Kurtz DM
Cancer Treat Rev; 2020 Dec; 91():102106. PubMed ID: 33049623
[TBL] [Abstract][Full Text] [Related]
9. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
[TBL] [Abstract][Full Text] [Related]
11. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
[TBL] [Abstract][Full Text] [Related]
12. Implementing circulating tumor DNA analysis in a clinical laboratory: A user manual.
Koessler T; Addeo A; Nouspikel T
Adv Clin Chem; 2019; 89():131-188. PubMed ID: 30797468
[TBL] [Abstract][Full Text] [Related]
13. Genomic Landscape of Liquid Biopsy for Hepatocellular Carcinoma Personalized Medicine.
Moldogazieva NT; Zavadskiy SP; Terentiev AA
Cancer Genomics Proteomics; 2021; 18(3 Suppl):369-383. PubMed ID: 33994362
[TBL] [Abstract][Full Text] [Related]
14. Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies.
Abbou SD; Shulman DS; DuBois SG; Crompton BD
Pediatr Blood Cancer; 2019 May; 66(5):e27595. PubMed ID: 30614191
[TBL] [Abstract][Full Text] [Related]
15. The Role of Circulating Tumor DNA in Lung Cancer: Mutational Analysis, Diagnosis, and Surveillance Now and into the Future.
Scilla KA; Rolfo C
Curr Treat Options Oncol; 2019 Jun; 20(7):61. PubMed ID: 31203467
[TBL] [Abstract][Full Text] [Related]
16. Dynamic Treatment Stratification Using ctDNA.
Vidal J; Taus A; Montagut C
Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
[TBL] [Abstract][Full Text] [Related]
17. Liquid Biopsy for Advanced Cancer: An Amplicon-Based Massively Parallel Sequencing Panel Approach to Precision Oncology.
Maurer K; Schandl CA
Methods Mol Biol; 2023; 2621():111-126. PubMed ID: 37041443
[TBL] [Abstract][Full Text] [Related]
18. Comparison of solid tissue sequencing and liquid biopsy accuracy in identification of clinically relevant gene mutations and rearrangements in lung adenocarcinomas.
Lin LH; Allison DHR; Feng Y; Jour G; Park K; Zhou F; Moreira AL; Shen G; Feng X; Sabari J; Velcheti V; Snuderl M; Cotzia P
Mod Pathol; 2021 Dec; 34(12):2168-2174. PubMed ID: 34362997
[TBL] [Abstract][Full Text] [Related]
19. Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients.
Papadopoulou E; Tsoulos N; Tsantikidi K; Metaxa-Mariatou V; Stamou PE; Kladi-Skandali A; Kapeni E; Tsaousis G; Pentheroudakis G; Petrakis D; Lampropoulou DI; Aravantinos G; Varthalitis I; Kesisis G; Boukovinas I; Papakotoulas P; Katirtzoglou N; Athanasiadis E; Stavridi F; Christodoulou C; Koumarianou A; Eralp Y; Nasioulas G
PLoS One; 2019; 14(12):e0226853. PubMed ID: 31860648
[TBL] [Abstract][Full Text] [Related]
20. Circulating Tumor DNA as a Liquid Biopsy: Current Clinical Applications and Future Directions.
Komatsubara KM; Sacher AG
Oncology (Williston Park); 2017 Aug; 31(8):618-27. PubMed ID: 28812303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
